Business Context and Reporting Period
Company: Novo Nordisk A/S
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: August 4, 2026
Period Covered: Second Quarter 2026 (Q2 2026) and Full Year 2026 Outlook
Novo Nordisk, a global healthcare company headquartered in Denmark, reported its Q2 2026 financial results and updated its full-year 2026 guidance. The company focuses on defeating serious chronic diseases, with a heritage in diabetes and a growing portfolio of GLP-1 products.
Key Financial Metrics
| Metric (DKK Million) | Q2 2026 Value | Growth at CER |
|---|---|---|
| Adjusted Sales | 78,488 | 7% |
| Adjusted Operating Profit | 33,389 | 11% |
Note: CER = Constant Exchange Rates. Growth rates exclude non-recurring impacts from 340B Drug Pricing Program provision reversals in the US.
Unusual Items: The Q2 2026 adjusted operating profit excludes DKK 6.3 billion in non-recurring, non-cash impairment charges related to intangible pipeline assets, including DKK 4.0 billion for monlunabant.
Material Changes vs. Prior Period
- Revenue Growth: Adjusted sales increased by 7% at CER compared to the prior year period.
- Profit Growth: Adjusted operating profit increased by 11% at CER compared to the prior year period.
- Guidance Revision: The company raised its full-year 2026 outlook for both adjusted sales and adjusted operating profit growth compared to expectations issued on May 6, 2026.
Guidance, Outlook, and Management Commentary
Full Year 2026 Outlook (at CER):
- Adjusted Sales Growth: Revised to 0% to -6% (previously -4% to -12%).
- Adjusted Operating Profit Growth: Revised to 0% to -6% (previously -4% to -12%).
Management Commentary: The improved outlook is driven by increased expectations for GLP-1 product sales. On a non-adjusted basis, the mid-point of sales and operating profit growth guidance for 2026 would be 5% and 12%, respectively.
Risks and Contingencies: Forward-looking statements are subject to assumptions described in the financial report for the first three months of 2026 (Company Announcement No 30/2026). The filing references standard risks associated with forward-looking statements.
Key Facts for Investor Verification
- Verify the specific impact of the DKK 6.3 billion impairment charge on non-adjusted operating profit figures.
- Confirm the detailed breakdown of GLP-1 product sales driving the revised full-year outlook.
- Review the full financial report for the first six months of 2026, scheduled for publication on August 4, 2026, for comprehensive liquidity and debt metrics not detailed in this summary.
- Monitor the conference call scheduled for August 5, 2026, for further management commentary on the 340B Drug Pricing Program impacts.